 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 10,250 shares of the companys common stock to a new employee as an inducement award under the companys 2019 Inducement Plan. In addition, the company granted a non-statutory stock option for the purchase of up to 130,000 